Proactive Investors - Run By Investors For Investors

Humanigen study of its monoclonal antibody in CAR-T therapy featured in medical journal

The study involving lenzilumab showed a reduction in cytokine release syndrome and neuroinflammation as well as an enhancement in CAR-T cell function
Dr Cameron Durrant
Dr Cameron Durrant, CEO of Humanigen, says the study marks a ‘significant advance’

Humanigen Inc (OTCMKTS:HGEN) said  Friday that the editors of the medical journal blood featured on the cover of the current edition, a study of the use of the company's proprietary monoclonal antibody.

The biotech’s lenzilumab monoclonal antibody is designed to reduce the sometimes dangerous side-effects associated with a cancer therapy involving altered T cells. The study involving lenzilumab showed a reduction in cytokine release syndrome and neuroinflammation as well as an enhancement in CAR-T cell function, according to the Burlingame, California, company.

READ: Sonavex to begin commercial roll-out of its blood clot detection device Q1 2019

The study, conducted with lab mice, was designed to replicate the effects seen in CAR-T clinical trials. It used human acute lymphoblastic leukemia cells, human CD19 targeted CAR-T (CART19) cells and human peripheral blood mononuclear cells.

The use of lenzilumab with CART19 therapy resulted in significant improvement in leukemic disease control, sustained for at least 35 days after CART19 administration, compared with a control, according to Humanigen.  

“This work represents a significant advance in understanding how to improve efficacy and safety of CAR-T,” Dr Cameron Durrant, CEO of Humanigen, said in a statement.

Shares of the company rose 1.1% to $0.93 in Thursday’s OTC Markets trading.

Contact Dennis Fitzgerald at [email protected]

View full HGEN profile View Profile

Humanigen Inc Timeline

Related Articles

dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
genedrive device
May 23 2019
Here we take a closer look at Genedrive PLC (LON:GDR)
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use